ArticleACS omega2026
Cyclodextrin Nanosponge-PVA Hybrid Networks as Supramolecular Reservoir Systems for Amitriptyline.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly-(vinyl alcohol) (PVA) hydrogels incorporating β-cyclodextrin (βCD) nanosponges (CDNSs) were developed as hybrid supramolecular systems for the controlled delivery of amitriptyline hydrochloride (AMT). The βCD-derived nanosponges provide host-guest cavities for drug inclusion, while the PVA network acts as a diffusion-regulating matrix. Initially, adsorption-desorption studies were performed on isolated CDNSs to evaluate their drug-loading capacity prior to incorporation into the hydrogels. The CDNSs exhibited efficient encapsulation (∼60%) and released more than 90% of the drug, confirming strong yet reversible host-guest interactions within CDs cavities. The drug-loaded CDNSs were subsequently dispersed in PVA solutions and physically cross-linked by freeze-thaw cycling, producing hydrogels containing embedded supramolecular reservoirs. Increasing the PVA concentration (from 14 to 20% w/v) generated denser polymer networks, reducing the swelling degree from ∼60 to ∼30 and slowing water uptake. CDNSs incorporation altered the hydrogel microstructure and introduced additional drug-matrix interactions, resulting in reduced burst release, measurable lag times, and more prolonged release compared with neat PVA hydrogels. Release kinetics were best described by the Weibull model, indicating diffusion-controlled transport in the pure matrices and heterogeneous diffusion behavior in the hybrid systems. Overall, AMT release is governed by coupled mechanisms involving diffusion through the polymer network and dissociation from cyclodextrin host sites, with CDNSs acting as supramolecular reservoirs within the hydrogel matrix.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.